CannTrust Holdings Inc (TSX: TRST)(NYSE: CTST) has named Dr Len Walt, MD, MBA as its new chief medical officer, it was reported yesterday.
Dr Walt will lead the global medical function dedicated to strengthening the company's clinical research strategy, medical education programs, product innovation and support the expansion of CannTrust's global medical businesses and partnerships.
Dr Walt comes to CannTrust with extensive senior leadership experience in the pharmaceutical and biotechnology industries in Canada, USA and abroad. Most recently he held the position of vice president and head of Medical Affairs at Sobi Inc, where he led the company's North American medical and scientific operations. Previously, he held the position of medical director at Biogen Canada, where he built medical teams and developed relationships with key clinical investigators in Canada.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business